Identifying the right treatment for your cancer patients – the benefits of comprehensive molecular profiling
Every patient is unique, reacting in different ways to the therapy they receive.
Every tumor is unique, with its own set of genomic and epigenomic alterations.
In the context of cancer treatment, this individuality represents a particular challenge due to the heterogeneity of tumors, which manifests as molecular alterations on multiple levels, including within the genome, transcriptome, and proteome. These molecular alterations are becoming an important part of treatment strategies, with several genomic markers already being used as part of standard-of-care treatment regimens (e.g. EGFR mutations in lung cancer). An expanding catalog of pre-clinical and clinical studies continues to identify other molecular markers with diagnostic and prognostic value, but they are not yet part of the routine clinical procedure. It is clear, however, that basing clinical decisions on a restricted range of mutations runs the risk of overlooking a large amount of clinically relevant information.
The approach of conducting a comprehensive molecular analysis of a patient and their tumor generates information that has a higher likelihood of significantly improving treatment strategies and outcomes. For example, comprehensive molecular profiling moves beyond a defined set of mutations to identify a range of known and as yet unknown alterations. These include predictive biomarkers (e.g. EGFR mutations) for targeted therapy, markers associated with immune-therapy or chemotherapy outcomes, prognostic (e.g. TP53 mutations) and diagnostic biomarkers (e.g. EWSR1 fusions) as well as predisposing mutations (e.g. BRCA mutations).
Due to rapid progress in sequencing technologies and analysis methods, comprehensive molecular profiling is now an affordable undertaking.
What we provide
The unique personalized analysis offered by Alacris Theranostics
We offer cancer genomics services for clinicians to provide a highly comprehensive molecular characterization of cancer patients, based on deep sequencing of the tumor transcriptome and genome, as well as of the patient genome.
Our Comprehensive Molecular Tumor Analysis (CMTA) generates a detailed molecular profile of each individual tumor. The CMTA is based on our cutting-edge powerful NGS analysis pipeline, which integrates Whole-Exome Sequencing (WES), shallow or full Whole-Genome Sequencing (WGS) and RNA Sequencing (RNAseq). We routinely employ both WES and shallow WGS of tumor and healthy control samples to call genomic aberrations, such as mutations, amplification, deletions or gene fusions. We also employ RNAseq to identify alterations in signaling pathways, gene over- or under-expression, and to support the identification of gene fusions. These results are reviewed by experts in bioinformatics, molecular biology, and oncology.
Complexity made simple
The CTMA delivers one clear and concise fully annotated report to the clinician containing the following multi-level molecular information:
- Mutations in genes and clinically-relevant regions of the genome
- Whole genome chromosome alterations (digital karyotype)
- Regions with loss of heterozygosity (LOH)
- Gene fusions
- Gene amplification and associated expression
- Full analysis of altered gene expression in the tumor
- Analysis of the tumor microenvironment and immune infiltration
- Biological annotation of the findings
- Annotation for approved targeted therapies and clinical trials
- Landscape of the tumor type and microenvironment
The results of the CMTA will impact clinical practice in different ways, depending on the patient, tumor type and stage. A discussion of the hopes and promises of personalized oncology as well as a preselection of patients who are most likely to benefit from comprehensive molecular diagnostics will, therefore, be key to successfully harnessing biomedical research for clinical routine.
The CMTA supplies clinicians with the necessary information to support their treatment decisions. The high-quality data interpretation and expert insight provided will facilitate identification of the best treatment option.
We are always available to answer any questions that might arise. Please contact us via firstname.lastname@example.org or by using the contact form below.181201_AL_CMTA_2_2018_E_LY4